Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Achillion Rises as Hepatitis Drug Field Winnows


Idenix shares drop as Wall Street shifts focus to rival hepatitis C drug developer.

MINYANVILLE ORIGINAL Shares of hepatitis C drug developer Achillion Pharmaceuticals (ACHN) are rising after at least two Wall Street analysts recommended buying the stock.

Rival Idenix Pharmaceuticals (IDIX), on the other hand, is dropping after seeing its buy recommendation lowered to a hold at Bank of America-Merrill Lynch. BofA and Deutsche Bank both recommended buying Achillion.

Achillion's stock rose 16% to $9.40 in morning trading Wednesday. The stock jumped more than 50% in the past month. Idenix shares fell more than 11% to $5 in morning trading. The stock has lost more than half its value since the end of July.

The ratings and stock movements are the latest sentiment shift among the field of drug developers racing to bring the next-generation of hepatitis C treatments to market. Bristol-Myers Squibb (BMY) recently dropped out of the race because of safety concerns around its drug. Idenix has two drugs that are being scrutinized by US officials because of concerns that they may pose similar threats. It should be noted that no such safety issue has actually materialized among the Indenix drugs. (See Idenix Drops After FDA Puts Hold on Another Hepatitis Drug.)

Many investors are betting that Gilead Sciences (GILD), long known for its HIV drugs, is in the best position to win approval for a better treatment following its $11 billion takeover of Pharmasset earlier this year. (See Gilead Sciences Makes Headlines With HIV Prevention Pill, Looks to Hepatitis Drugs for Future.)

Gilead, Vertex Pharmaceuticals (VRTX), and Idenix are all testing drugs known as nucleotide polymerase inhibitors. Bristol-Myers was testing a hepatitis drug in the same class. The drugs target an enzyme needed for the hepatitis C virus to replicate.

Achillion's lead drug isn't in this same class and neither is an experimental treatment being tested by Abbott Laboratories (ABT). There's no indication so far that the entire class of "nucs" being developed by Gilead, Vertex, and Idenix have safety issues. In fact, Gilead execs point to the large pool of patients that have already been tested with the company's lead drug to show that the treatment doesn't appear to have toxicity problems. Still, Achillion and Abbott offer alternative approaches to those other companies' drugs.

For each one of these companies, the goal is to create an all-oral regimen for hepatitis C patients that eliminates the need for interferon, an injected therapy that causes flu-like symptoms.

Millions of Americans are believed to be chronically infected with the liver-destroying virus and many of them were exposed decades ago. As many as 170 million people worldwide are estimated to have chronic infections.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos